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Adefovir Dipivoxil for the Treatment
of Hepatitis B e Antigen–Positive
Chronic Hepatitis B
Patrick Marcellin, M.D., Ting-Tsung Chang, M.D., Seng Gee Lim, M.D.,
Myron J. Tong, Ph.D., M.D., William Sievert, M.D., Mitchell L. Shiffman, M.D.,
Lennox Jeffers, M.D., Zachary Goodman, M.D., Ph.D.,
Michael S. Wulfsohn, M.D., Ph.D., Shelly Xiong, Ph.D., John Fry, B.Sc.,
and Carol L. Brosgart, M.D., for the Adefovir Dipivoxil 437 Study Group*

abstract
background
From the Service d’Hépatologie, INSERM
Unité 481, and Centre de Recherches Claude
Bernard sur les Hépatites Virales, Hôpital
Beaujon, Clichy, France (P.M.); the Department of Internal Medicine, National Cheng
Kung University Hospital, Tainan, Taiwan
(T.-T.C.); the Division of Gastroenterology,
National University Hospital, Singapore
(S.G.L.); the Liver Center, Huntington Medical Research Institutes, Pasadena, Calif.
(M.J.T.); the Department of Medicine,
Monash University and Monash Medical
Centre, Melbourne, Australia (W.S.); the
Division of Gastroenterology, Virginia Commonwealth University Health System, Richmond (M.L.S.); the Center for Liver Diseases, University of Miami School of Medicine,
and the Miami Veterans Affairs Medical
Center, Miami (L.J.); the Armed Forces Institute of Pathology, Washington, D.C.
(Z.G.); and Gilead Sciences, Foster City,
Calif. (M.S.W., S.X., J.F., C.L.B.). Address
reprint requests to Dr. Marcellin at the Service d’Hépatologie, INSERM Unité 481, and
Centre de Recherches Claude Bernard sur
les Hépatites Virales, Hôpital Beaujon, 100
Blvd. du Général Leclerc, 92110 Clichy,
France, or at marcellin@bichat.inserm.fr.
*Other members of the Adefovir Dipivoxil 437 Study Group are listed in the Appendix.

In preclinical and phase 2 studies, adefovir dipivoxil demonstrated potent activity against
hepatitis B virus (HBV), including lamivudine-resistant strains.
methods

We randomly assigned 515 patients with chronic hepatitis B who were positive for hepatitis B e antigen (HBeAg) to receive 10 mg of adefovir dipivoxil (172 patients), 30 mg
of adefovir dipivoxil (173), or placebo (170) daily for 48 weeks. The primary end point
was histologic improvement in the 10-mg group as compared with the placebo group.
results

After 48 weeks of treatment, significantly more patients who received 10 mg or 30 mg
of adefovir dipivoxil per day than who received placebo had histologic improvement
(53 percent [P<0.001], 59 percent [P<0.001], and 25 percent, respectively), a reduction
in serum HBV DNA levels (by a median of 3.52 [P<0.001], 4.76 [P<0.001], and 0.55 log
copies per milliliter, respectively), undetectable levels (fewer than 400 copies per milliliter) of serum HBV DNA (21 percent [P<0.001], 39 percent [P<0.001], and 0 percent, respectively), normalization of alanine aminotransferase levels (48 percent [P<0.001], 55
percent [P<0.001], and 16 percent, respectively), and HBeAg seroconversion (12 percent
[P=0.049], 14 percent [P=0.01], and 6 percent, respectively). No adefovir-associated
resistance mutations were identified in the HBV DNA polymerase gene. The safety profile of the 10-mg dose of adefovir dipivoxil was similar to that of placebo; however,
there was a higher frequency of adverse events and renal laboratory abnormalities in
the group given 30 mg of adefovir dipivoxil per day.
conclusions
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In patients with HBeAg-positive chronic hepatitis B, 48 weeks of 10 mg or 30 mg of adefovir dipivoxil per day resulted in histologic liver improvement, reduced serum HBV DNA
and alanine aminotransferase levels, and increased the rates of HBeAg seroconversion.
The 10-mg dose has a favorable risk–benefit profile for long-term treatment. No adefovir-associated resistance mutations were identified in the HBV DNA polymerase gene.

n engl j med 348;9

www.nejm.org

february 27, 2003

The New England Journal of Medicine
Downloaded from nejm.org at VIRGINIA COMMONWEALTH UNIV on January 14, 2015. For personal use only. No other uses without permission.
Copyright © 2003 Massachusetts Medical Society. All rights reserved.

adefovir dipivoxil for chronic hepatitis b

m

ore than 350 million people
worldwide have chronic hepatitis B virus
(HBV) infection.1 Effective treatments
are required to prevent progression of chronic hepatitis B to cirrhosis, hepatocellular carcinoma, and
death. Treatment with interferon alfa requires parenteral administration and can cause side effects,
such as influenza-like symptoms, anorexia, and depression, that require an adjustment in the dose or
discontinuation of therapy.2 The risk of progressive
liver damage decreases in patients who have hepatitis B e antigen (HBeAg) seroconversion after interferon therapy. Lamivudine suppresses HBV replication and improves histologic liver findings.3
However, lamivudine resistance has been reported
in up to 32 percent of patients after one year of therapy4 and in 66 percent after four years.5 Some patients with lamivudine resistance have had a severe
exacerbation of hepatitis and progressive liver disease.6 Therefore, well-tolerated antiviral agents that
provide clinical benefit without inducing resistance
are needed to manage chronic hepatitis B.
Adefovir dipivoxil (Hepsera, Gilead Sciences) is
an oral prodrug of adefovir, an analogue of adenosine monophosphate. The active intracellular metabolite, adefovir diphosphate, inhibits HBV DNA
polymerase at levels much lower than those needed
to inhibit human DNA polymerases. In phase 2
studies, daily doses of 30 mg and 60 mg of adefovir
dipivoxil inhibited HBV replication, reducing serum
HBV DNA by approximately 4 log copies per milliliter after 12 weeks.7 Adefovir dipivoxil has also
been efficacious in patients with lamivudine-resistant HBV.8
We elected to evaluate in a double-blind, placebocontrolled study the effects of 10-mg and 30-mg
doses of adefovir dipivoxil in patients with HBeAgpositive chronic hepatitis B on the basis of the results of phase 2 studies, which showed that the antiviral activity of doses greater than or equal to 30 mg
was similar. During the long-term, phase 2 study,
data indicated that the 30-mg dose was associated
with mild, reversible nephrotoxicity after 32 weeks.
Therefore, we amended the primary end point for
this study before the analysis and unblinding, to
compare a 10-mg dose of adefovir dipivoxil with
placebo. We report the 48-week results, but the
study is ongoing and will continue for up to 5 years.
When the study was designed, lamivudine was still
an investigational agent; therefore, placebo was selected as the control.

n engl j med 348;9

methods
study design

From March 1999 to March 2000, patients were recruited from 78 centers in North America, Europe,
Australia, and Southeast Asia and randomly assigned in a 1:1:1 ratio to receive 10 mg of adefovir
dipivoxil per day, 30 mg of adefovir dipivoxil per day,
or placebo. The central randomization scheme was
stratified according to seven geographic regions.
Permuted blocks (with a block size of six) were used
in each stratum. The placebo and adefovir dipivoxil
tablets were formulated to be indistinguishable
from one another in appearance and taste.
The study was conducted in compliance with the
Declaration of Helsinki and approved by appropriate local regulatory bodies. All patients provided
written informed consent. Liver biopsy was performed at base line and week 48. Biopsy specimens
obtained within six months before randomization
could be used if they had been obtained more than
six months after the completion of prior hepatitis B
therapy. Patients were evaluated every four weeks.
Clinical data were collected, monitored, and entered into a data base by Quintiles. Laboratory tests
were conducted by Covance. The sponsor held the
data and conducted the statistical analyses, which
were predefined; the academic investigators had full
access to the data and contributed substantially to
the design of the study, the collection of the data, the
analysis and interpretation of the data, and the drafting of the manuscript. All authors approved the final draft of the manuscript.
patients

Male and female patients 16 to 65 years of age who
had hepatitis B e antigen–positive chronic hepatitis B and compensated liver disease were eligible for
the study. Chronic hepatitis B was defined by the
presence of serum hepatitis B surface antigen for at
least six months, a serum HBV DNA level of at least
1 million copies per milliliter (measured with the
Roche Amplicor Monitor polymerase-chain-reaction [PCR] assay), and a serum alanine aminotransferase level that was 1.2 to 10 times the upper limit
of the normal range. Patients were required to have
a prothrombin time that was no more than one second above the normal range, a serum albumin level
of at least 3 g per deciliter, a total bilirubin level of
no more than 2.5 mg per deciliter (43 µmol per liter), a serum creatinine level of no more than 1.5 mg
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per deciliter (133 µmol per liter), and an adequate
blood count. Women of childbearing potential were
eligible if they had a negative pregnancy test and
were using effective contraception.
Criteria for exclusion included a coexisting serious medical or psychiatric illness; immune globulin, interferon, or other immune- or cytokine-based
therapies with possible activity against HBV disease
within 6 months before screening; organ or bone
marrow transplantation; recent treatment with
systemic corticosteroids, immunosuppressants, or
chemotherapeutic agents; a serum alpha-fetoprotein level of at least 50 ng per milliliter; evidence of
a hepatic mass; liver disease that was not due to hepatitis B; prior therapy for more than 12 weeks with
a nucleoside or nucleotide analogue with activity
against HBV; and seropositivity for human immunodeficiency virus or hepatitis C or D virus.
end points

The primary efficacy end point was histologic improvement, defined as a reduction of at least two
points in the Knodell necroinflammatory score with
no concurrent worsening of the Knodell fibrosis
score 48 weeks after base line.9 The liver-biopsy
specimens were evaluated by an independent histopathologist who was unaware of the patients’ treatment assignments or of the timing of liver biopsy.
Ranked assessments of necroinflammatory activity
and fibrosis were also performed (and scored as improved, no change, or worse).
Secondary end points included the change from
base line in serum HBV DNA levels, the proportion
of patients with undetectable levels of HBV DNA,
the effect of treatment on the alanine aminotransferase level, and the proportion of patients with loss
or seroconversion of HBeAg. Serum HBV DNA levels were measured by the Roche Amplicor HBV
Monitor PCR assay (lower limit of detection, 400
copies per milliliter), and the values were log-transformed with use of a base 10 scale.
safety analysis

of

medicine

detection of hbv polymerase mutations

All serum samples obtained at base line and week
48 were examined in a blinded fashion. HBV DNA
was isolated and amplified by PCR. The positive and
negative strands of the HBV polymerase gene spanning the polymerase–reverse-transcriptase domain
(amino acids 349 to 692) were sequenced. The HBV
sequences of the samples obtained at base line and
week 48 from the same patient were aligned with
the MegAlign program (DNAStar).
statistical analysis

The study was designed to enroll 166 patients per
group, with 90 percent power to detect an absolute
difference of 20 percent (50 percent vs. 30 percent)
between the group given 10 mg of adefovir dipivoxil
and the placebo group, assuming that 25 percent of
patients would have missing biopsy specimens that
would be considered treatment failures and that
8 percent of patients would have missing base-line
biopsy specimens, on the basis of a two-sided type I
error rate of 0.05. The study had 79 percent power
to detect an absolute difference of 10 percent (16
percent vs. 6 percent) in the rate of seroconversion
between the group given 10 mg of adefovir dipivoxil
and the placebo group, assuming that 10 percent of
patients would have missing values (which were
counted as treatment failures). Patients who received at least one dose of study medication were
included in the analyses. Patients with missing or
unassessable base-line liver-biopsy specimens were
prospectively excluded from the primary efficacy
analysis. Patients with missing or unassessable data
at 48 weeks were considered not to have had responses. The unstratified Cochran–Mantel–Haenszel test was used to compare each of the adefovir
dipivoxil groups with the placebo group. All P values were two-sided. No adjustments were made for
multiple comparisons. All serum HBV DNA results
below the lower limit of detection (less than 400
copies per milliliter) were analyzed as being 400
copies per milliliter. No interim analyses were performed other than safety-data summaries, which
were prepared every six months for a review by the
independent external data-monitoring committee.

The primary safety analysis included all patients
who received at least one dose of study medication
and all events that occurred during treatment or
within 30 days after the discontinuation of study
results
drug. The severity of adverse events and laboratory
abnormalities was graded according to the Com- characteristics of the patients
mon Toxicity Criteria of the National Institute of Al- Among the 515 patients who were enrolled, 172
lergy and Infectious Diseases.10
were randomly assigned to receive 10 mg of adef-
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ovir dipivoxil per day, 173 to receive 30 mg per day,
and 170 to receive placebo. Four patients took no
study medication (one in the 10-mg group and three
in the placebo group). Of the remaining 511 patients, base-line biopsy specimens were available for
168 patients in the 10-mg group, 165 in the 30-mg
group, and 161 in the placebo group. There were no
significant differences in demographic or HBV disease characteristics (Table 1) or previous anti-HBV
treatments among the groups. A total of 123 patients (24 percent) had received treatment with interferon alfa.
histologic response

The primary analysis was based on the 329 patients
(97 percent) in the group given 10 mg of adefovir
dipivoxil and the placebo group for whom base-line
liver-biopsy specimens were available. Histologic
improvement was seen in 53 percent of patients in
the group given 10 mg of adefovir dipivoxil, 25 percent of those in the placebo group (P<0.001) (Table 2), and 59 percent of those in the group given
30 mg of adefovir dipivoxil (P<0.001). The results
were not changed by the addition of the four patients who underwent randomization but who did
not take any study medication.
After 48 weeks, patients who received 10 mg of
adefovir dipivoxil per day had a median reduction in
the Knodell necroinflammatory score of two points
and those who received 30 mg per day had a median
reduction of three points, as compared with no
change in the placebo group (P<0.001 for both comparisons) (Table 2). On ranked assessment, higher
percentages of patients in the 10-mg group and the
30-mg group than in the placebo group had improvements in necroinflammatory activity and fibrosis, and a higher percentage of patients in the
placebo group had worsening of necroinflammatory activity and fibrosis (P<0.001 for each comparison).

Table 1. Base-Line Characteristics of the Patients.*

Characteristic

Placebo
(N=167)

10 mg of
Adefovir
Dipivoxil
(N=171)

Age — yr
Mean ±SD
Median
Range

37±11.8
35
16–66

34±11.2
32
16–65

Male sex — no. (%)

119 (71)

130 (76)

129 (75)

Race or ethnic group — no. (%)
White
Black
Asian
Other

60 (36)
3 (2)
101 (60)
3 (2)

60 (35)
8 (5)
102 (60)
1 (1)

64 (37)
5 (3)
101 (58)
3 (2)

Weight — kg
Mean ±SD
Median
Range

30 mg of
Adefovir
Dipivoxil
(N=173)
34±10.8
32
17–68

70±14.9
70
41–134

72±15.9
71
43–118

139±131
94
3 (2)
164 (98)

139±154
95
3 (2)
168 (98)

124±96
92
4 (2)
169 (98)

3.4±3.1
2.4

3.4±4.0
2.3

3.0±2.3
2.3

HBV DNA — log copies/ml†
Mean ±SD
Median

8.12±0.89
8.33

8.25±0.90
8.40

8.22±0.84
8.34

Total Knodell score
Mean ±SD
Median
Range

9.65±3.45
10.0
1–17

9.01±3.33
9.5
0–17

9.55±3.33
10.0
0–16

Knodell necroinflammatory score
Mean ±SD
Median
Range

7.83±2.89
8.0
1–14

7.37±2.75
7.0
0–14

7.84±2.82
8.0
0–12

Knodell fibrosis score
Mean ±SD
Median
Range

1.83±1.12
1.0
0–4

1.64±1.09
1.0
0–4

1.71±1.06
1.0
0–4

Alanine aminotransferase
Mean ±SD — U/liter
Median — U/liter
≤ULN — no. (%)
>ULN — no. (%)
Multiples of ULN
Mean ±SD
Median

69±15.9
67
40–129

* ULN denotes upper limit of the normal range, and HBV hepatitis B virus.
† Values were log-transformed with use of a base 10 scale.

virologic response

At week 48, serum HBV DNA levels had decreased
by a median of 3.52 log copies per milliliter in the
group given 10 mg of adefovir dipivoxil and 4.76 log
copies per milliliter in the 30-mg group, as compared with 0.55 log copies per milliliter in the placebo group (P<0.001 for each comparison) (Table 3
and Fig. 1). Twenty-one percent of the patients in the
10-mg group and 39 percent of those in the 30-mg
group had undetectable serum levels of HBV DNA,
as compared with 0 percent of the patients in the

n engl j med 348;9

placebo group (P<0.001 for each comparison). Loss
of HBeAg occurred in 24 percent of the patients in
the 10-mg group and 27 percent of those in the
30-mg group, as compared with 11 percent of the
patients in the placebo group (P<0.001 for each
comparison). HBeAg seroconversion occurred in 12
percent of the patients in the 10-mg group and 14
percent of those in the 30-mg group, as compared
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Table 2. Histologic Improvement and Changes in Necroinflammatory Activity and Fibrosis from Base Line to Week 48.*

Variable

Placebo

10 mg of
Adefovir Dipivoxil

30 mg of
Adefovir Dipivoxil

161

168

165

41 (25)

89 (53)

98 (59)

105 (65)

61 (36)

47 (28)

14 (9)

16 (10)

16 (10)

1 (1)

2 (1)

4 (2)

2.1
1.5 to 2.8

2.3
1.7 to 3.1

<0.001

<0.001

2.1
1.6 to 2.8

2.3
1.7 to 3.1

<0.001

<0.001

146
¡0.16±3.06
0
¡10 to 7

150
¡2.58±3.22
¡2
¡9 to 6
<0.001

145
¡3.17±3.30
¡3
¡9 to 5
<0.001

145
59 (41)
37 (26)
49 (34)

150
107 (71)
23 (15)
20 (13)
<0.001

145
112 (77)
18 (12)
15 (10)
<0.001

146
¡0.01±0.86
0
¡3 to 2

150
¡0.18±0.84
0
¡2 to 2
0.061

145
¡0.32±0.80
0
¡2 to 2
0.001

145
35 (24)
72 (50)
38 (26)

150
62 (41)
67 (45)
21 (14)
<0.001

145
78 (54)
53 (37)
14 (10)
<0.001

Histologic improvement†
No. of patients‡
Histologic improvement — no. (%)
No improvement — no. (%)
Missing data — no. (%)
Unassessable data — no. (%)
Unstratified relative risk
95% CI
P value
Stratum-adjusted relative risk
95% CI§
P value
Necroinflammatory activity
Knodell score
No. of patients¶
Mean (±SD) change in score
Median change in score
Range of scores
P value¿
Ranked assessment
No. of patients¶
Improved — no. (%)
No change — no. (%)
Worse — no. (%)
P value¿
Fibrosis
Knodell score
No. of patients¶
Mean (±SD) change in score
Median change in score
Range of scores
P value¿
Ranked assessment
No. of patients¶
Improved — no. (%)
No change — no. (%)
Worse — no. (%)
P value¿

* Relative risks and P values are for the comparison with the placebo group. CI denotes confidence interval.
† Histologic improvement was defined as a decrease of at least two points in the Knodell necroinflammatory score from
base line to week 48, with no concurrent worsening of the Knodell fibrosis score. Patients who did not satisfy this definition were considered not to have histologic improvement. Patients with missing or unassessable data at week 48 were
considered not to have had histologic improvement in the comparison between each adefovir dipivoxil group and the
placebo group.
‡ The number of patients is the number with assessable liver-biopsy specimens at base line.
§ Values were adjusted for the seven geographic regions involved in the study (Europe, the United States, Canada, Australia,
Taiwan, Thailand, and other parts of Asia [Singapore, the Philippines, and Malaysia]).
¶ The number of patients is the number with assessable liver-biopsy specimens at base line and week 48.
¿ P values are from the general-association Cochran–Mantel–Haenszel statistic for comparisons of the 10-mg group or
the 30-mg group with the placebo group. All P values are two-sided at a significance level of 0.05, with no adjustments for
multiple comparisons.
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with 6 percent of the patients in the placebo group
(P=0.049 and P=0.011, respectively).

Table 3. Virologic and Biochemical Responses at Week 48.*

biochemical response

Median reductions in serum alanine aminotransferase levels at week 48 were 51 IU per liter in the 10mg group and 54 IU per liter in the 30-mg group, as
compared with 17 IU per liter in the placebo group
(P<0.001 for each comparison) (Table 3). Fortyeight percent of the patients who received 10 mg of
adefovir dipivoxil per day and 55 percent of those
who received 30 mg per day had normal alanine
aminotransferase values at week 48, as compared
with 16 percent of those who received placebo (P<
0.001 for both comparisons).
resistance profile

The polymerase–reverse transcriptase domain of
the HBV polymerase gene was sequenced from serum samples obtained at base line and week 48 in
381 patients with detectable serum HBV DNA at
both times. No mutations occurred at higher than
background frequencies (less than 1.6 percent).
Seven different novel substitutions were found at
conserved sites in the HBV polymerase in seven patients (four of whom received adefovir dipivoxil and
three of whom received placebo). All four of the patients who received adefovir dipivoxil had significant reductions in serum HBV DNA levels at week
48. In vitro phenotypic analyses demonstrated that
viruses containing any of the seven substitutions remained fully susceptible to adefovir.
safety

Similar percentages of patients in each group discontinued the study prematurely: 7 percent of those
given 10 mg of adefovir dipivoxil per day and 8 percent of those given 30 mg per day and those given
placebo. The incidence of severe (grade 3 or 4) clinical adverse events was similar: 10 percent in patients who received 10 mg of adefovir dipivoxil per
day, 9 percent in those who received 30 mg per day,
and 8 percent in the placebo group. The safety profile of the 10-mg group was similar to that of placebo with respect to all reported adverse events except
asthenia (25 percent in the 10-mg group vs. 19 percent in the placebo group) and diarrhea (13 percent
vs. 8 percent) (Table 4). Anorexia (10 percent) and
pharyngitis (40 percent) occurred more frequently
in the 30-mg group. Adverse events leading to the
discontinuation of the study drug occurred in 2 percent of the patients in the 10-mg group, 3 percent of

n engl j med 348;9

Variable

Placebo
(N=167)

10 mg
of Adefovir
Dipivoxil
(N=171)

30 mg
of Adefovir
Dipivoxil
(N=173)

Virologic response
Change in serum HBV DNA
— log copies/ml
Mean ±SD
Median
95% CI
P value

¡0.98±1.32
¡3.57±1.64
¡4.45±1.62
¡0.55
¡3.52
¡4.76
¡1.20 to ¡0.77 ¡3.84 to ¡3.31 ¡4.72 to ¡4.19
<0.001
<0.001

Serum HBV DNA <400 copies/
ml — no. (%)
P value†

0

HBeAg seroconversion — no./
total no. (%)‡§
P value†
HBeAg loss — no./total no.
(%)‡
P value†

36 (21)

67 (39)

<0.001

<0.001

9/161 (6)

20/171 (12)

23/165 (14)

<0.049

<0.011

17/161 (11)

41/171 (24)

44/165 (27)

<0.001

<0.001

Biochemical response
Change in serum alanine
aminotransferase level
— IU/liter
Mean ±SD
Median
95% CI
P value
Normalization of alanine
aminotransferase
— no./total no. (%)¶
P value†

¡23.0±140.7 ¡92.1±167.2 ¡74.4±128.4
¡17
¡51
¡54
¡45.9 to ¡0.2 ¡118.8 to ¡65.3 ¡95.6 to ¡53.3
<0.001
<0.001
26/164 (16)

81/168 (48)

93/169 (55)

<0.001

<0.001

* HBV denotes hepatitis B virus, and CI confidence interval.
† P values are from the general-association Cochran–Mantel–Haenszel statistic
for comparisons of each adefovir dipivoxil group with the placebo group. All
P values are two-sided at a significance level of 0.05, with no adjustments for
multiple comparisons.
‡ Patients who were positive for hepatitis B e antigen (HBeAg) at base line were
included in the analysis.
§ Seroconversion was defined as loss of HBeAg and concurrent gain of antibody
against HBeAg at 48 weeks.
¶ Patients with base-line alanine aminotransferase levels that exceeded the upper limit of the normal range were included in the analysis.

those in the 30-mg group, and less than 1 percent of
those in the placebo group. These events included
increased alanine aminotransferase or aspartate
aminotransferase levels, weight loss, and rash in the
10-mg group; nausea, abdominal pain, headache,
Fanconi-like syndrome, amblyopia, and myocardial
infarction in the 30-mg group; and nausea in the
placebo group.
There was no significant change in median serum creatinine levels at week 48 in the 10-mg group
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Change in HBV DNA (log copies/ml)

1
0

Placebo

¡1
¡2
10 mg of adefovir dipivoxil
¡3

P<0.001

¡4

30 mg of adefovir dipivoxil
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Figure 1. Mean Change from Base Line in Serum Levels of Hepatitis B Virus
(HBV) DNA.
I bars are 95 percent confidence intervals. P values are for the comparison
with placebo.

Table 4. Adverse Events Reported by at Least 10 Percent of Patients
in the Group Given 30 mg of Adefovir Dipivoxil per Day.

Adverse Event

Placebo
(N=167)

10 mg of
Adefovir
Dipivoxil
(N=171)

30 mg of
Adefovir
Dipivoxil
(N=173)

number of patients (percent)
Body as a whole
Headache
Asthenia
Abdominal pain
Flu-like syndrome
Pain
Back pain

37 (22)
32 (19)
32 (19)
31 (19)
21 (13)
11 (7)

43 (25)
42 (25)
31 (18)
28 (16)
19 (11)
11 (6)

45 (26)
45 (26)
38 (22)
32 (18)
13 (8)
17 (10)

Digestive tract
Nausea
Diarrhea
Dyspepsia
Flatulence
Anorexia

23 (14)
13 (8)
14 (8)
10 (6)
9 (5)

17 (10)
23 (13)
15 (9)
13 (8)
6 (4)

31 (18)
25 (14)
19 (11)
18 (10)
18 (10)

Nervous system
Dizziness

13 (8)

9 (5)

18 (10)

Respiratory tract
Pharyngitis
Increased cough

54 (32)
21 (13)

44 (26)
11 (6)

70 (40)
19 (11)
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and the placebo group; the 30-mg group had a median increase of 0.2 mg per deciliter (18 µmol per liter). There were no increases from base line of 0.5
mg per deciliter (44 µmol per liter) or greater in the
serum creatinine level (confirmed by two consecutive laboratory assessments) in the 10-mg group or
the placebo group, but 8 percent of patients in the
30-mg group had such an increase (P<0.001). In all
cases, renal function normalized with a dose reduction or an interruption of treatment. The maximal
reported serum creatinine level was 1.8 mg per deciliter (159 µmol per liter) in a patient in the 30-mg
group. There was a median increase in serum phosphorus of 0.1 mg per deciliter (0.03 mmol per liter)
in the 10-mg group and the placebo group and a median decrease of 0.1 mg per deciliter in the 30-mg
group. There were no confirmed instances of serum
phosphorus levels below 2.0 mg per deciliter (0.65
mmol per liter). The incidence of grade 3 or 4 laboratory abnormalities was similar in the adefovir
dipivoxil and placebo groups, except that aspartate
aminotransferase and alanine aminotransferase levels were higher in the placebo group.
Increases in alanine aminotransferase levels to
more than 10 times the upper limit of the normal
range occurred in 10 percent of patients in the group
given 10 mg of adefovir dipivoxil per day, 8 percent
of those given 30 mg per day, and 19 percent of those
given placebo. Concurrent changes in total bilirubin
levels, serum albumin levels, or the prothrombin
time were not seen in any patient in the 10-mg or
30-mg group. In the placebo group, one patient had
a concurrent increase in the total bilirubin level to
greater than 2.5 mg per deciliter and to at least 1 mg
per deciliter (17.1 µmol per liter) above the base-line
value, and one had a concurrent decrease in the serum albumin level (to less than 3.0 g per liter).
After week 48, all patients were reassigned to
new treatment groups for the second 48 weeks of
the study. All patients in the placebo group received
10 mg of adefovir dipivoxil per day. Patients in the
10-mg group were randomly assigned to receive either continued treatment with 10 mg per day or
placebo. All patients in the 30-mg group received
placebo.
An interim analysis of data from the second 48week period showed a continued antiviral, serologic, and biochemical response in patients who continued to receive 10 mg of adefovir dipivoxil per day
(median duration of additional therapy, 16 weeks).
By week 72, 46 percent of patients had fewer than
400 copies of serum HBV DNA per milliliter, 75 per-
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cent had normalization of alanine aminotransferase levels, 44 percent had loss of HBeAg, and 23 percent had HBeAg seroconversion. Safety data from
the second 48-week period were similar to those in
the first 48 weeks.

discussion
In patients with chronic hepatitis B, 48 weeks of
treatment with adefovir dipivoxil resulted in significant histologic improvement, reduced serum HBV
DNA levels, and increased normalization of alanine
aminotransferase levels and HBeAg seroconversion,
as compared with placebo. These results are similar
to those in the 52-week pivotal clinical trials of lamivudine.3,4 Lai et al. reported significant histologic improvement in 56 percent of patients after one
year of treatment with lamivudine, although the
development of serum HBV DNA polymerase mutations was associated with increases in alanine
aminotransferase and HBV DNA.3 Dienstag et al.
reported histologic improvement in 52 percent of
patients who received 100 mg of lamivudine per day;
anti-HBeAg antibodies developed in 17 percent, and
32 percent lost serum HBeAg.4
The patients in this study were from North America, Europe, Australia, and Southeast Asia; the majority were Asian. The two pivotal trials of lamivudine included predominantly white patients in the
United States4 or only Chinese patients.3 Several
studies have found regional and ethnic differences
in response to both HBV infection and treatments
for hepatitis B.11 The histologic improvement in our

patients was similar among the geographic regions;
therefore, our results may be more representative
of the global population of patients with chronic
hepatitis B. However, black patients were not well
represented.
The efficacy profile of the 10-mg and 30-mg
doses of adefovir dipivoxil was similar, except for
differences in the magnitude of the decrease in serum HBV DNA levels and the percentage of patients
with undetectable serum HBV DNA levels at 48
weeks. Both doses were well tolerated. However, the
increases in serum creatinine levels in the 30-mg
group limit the long-term use of this dose and instead favor the 10-mg dose. No adefovir-associated resistance mutations were identified during 48
weeks of treatment, which is consistent with findings from other studies evaluating up to 60 weeks
of treatment.12,13
In our study, treatment with 10 mg of adefovir
dipivoxil daily was well tolerated and significantly
improved histologic findings in the liver, reduced
serum HBV DNA levels, normalized alanine aminotransferase levels, and induced HBeAg loss and seroconversion in a diverse population. The favorable
resistance profile of adefovir dipivoxil during 48
weeks of therapy is an advantage, since many patients with chronic hepatitis B require long-term
therapy.
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